Muscle weakness and fatigue are the hallmarks of autoimmune neuromuscular junction
disorders. Although a plethora of immunosuppressive treatments exist, no cure is available …

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction (NMJ).
Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor …

Myasthenia gravis (MG) is a prototypical autoantibody mediated disease. The
autoantibodies in MG target structures within the neuromuscular junction (NMJ), thus …

When the diagnosis of myasthenia gravis (MG) has been secured, the aim of management
should be prompt symptom control and the induction of remission or minimal manifestations …

CBAs can lead to a significant reduction of seronegative patients, improving myasthenia
gravis diagnostic process. New biological drugs offer innovative approaches to treat …

The presence of autoantibodies directed against the muscle nicotinic acetylcholine receptor
(AChR) is the most common cause of myasthenia gravis (MG). These antibodies damage …

Introduction Myasthenia gravis (MG) is caused by IgG antibodies against different proteins at
the neuromuscular junction. Anti-acetylcholine receptor (AChR) Abs are detected in the …

Introduction: Myasthenia gravis (MG) is one of the best treatable autoimmune diseases.
However, in most patients, treatment is necessarily long-term and related side effects are a …

Introduction: Myasthenia gravis is a rare disease of the neuromuscular junction and a
prototype of B cell-driven immunopathology. Pathogenic antibodies target post-synaptic …

The mechanism of action of low-density lipoprotein receptor related protein 4 (LRP4) is
mediated largely via the Agrin-LRP4-MuSK signalling pathway in the nervous system. LRP4 …